Abstract. Human activation-inducible tumor necrosis factor (AITR) is a new member of the tumor necrosis factor family and expressed on peripheral blood mononuclear cells (PBMC) and leukocytes. Its ligand (AITRL) is expressed in endothelial cells. This study aimed to evaluate the presence and role of AITR and AITRL in patients with breast cancer. Expression of AITR and AITRL on PBMC and breast cancer cells was determined by flow cytometry, RT-PCR and fluorescence microscopy. Soluble (s) AITR and sAITRL were detected in serum of breast cancer patients by ELISA. AITR and AITRL were constitutively expressed in T cells, B cells, monocytes and monocyte-derived dendritic cells of breast cancer patients. AITRL was overexpressed in breast cancer cells. The levels of sAITRL were significantly increased in serum of breast cancer patients compared with the healthy control. This study suggests that AITR and AITRL may play an important role in tumor growth and survival in breast cancer.

Introduction

The members of the tumor necrosis factor (TNF) family are involved in the regulation of cell proliferation, differentiation and death and play a central role in the development of the immune response and in tumor killing (1). Human activation-inducible tumor necrosis factor receptor (AITR) is a new member of the TNF family such as CD27, CD40, 4-1BB and OX-40 and exhibits a high homology to murine glucocorticoid-induced TNF receptor family-related gene (GITR; TNFRSF18) (2). There is a mismatch in the first cysteine-rich pseudorepeat between GITR and AITR, because the first pseudorepeat of GITR corresponds to the first TNFR cysteine-rich motif (3). AITR is expressed in human peripheral blood mononuclear cells and leukocytes and is induced with T cell activation (2). AITR associates with TNF-receptor-associated factors (TRAF) such as TRAF1, TRAF2 and TRAF3 and the interaction of AITR with its ligand (AITRL) activates nuclear factor (NF)-κB via TRAF2 (2). NF-κB stimulates proliferation and blocks apoptosis in different cell types, including human breast cancers (4,5). Thus, breast cancer cells rely on NF-κB for aberrant cell proliferation and simultaneously avoid apoptosis (5). Overexpression of AITR mRNA was shown to rescue T cells from T cell receptor (TCR)-mediated cell death (2,3). AITR ligand (AITRL) cloned from a human brain cDNA library and found to be expressed in human endothelial cells provided costimulatory signal in T cells activation (2,3). However, AITR and AITRL are important for interaction between activated T lymphocytes and endothelial cells. Information on the biological functions of AITR and AITRL is limited. Based on GITR data, GITR as a receptor on the surface of CD4+CD25+ regulatory T cells (Treg) and can modulate Treg function in actively maintaining peripheral tolerance, GITR signaling had a costimulatory effect on purified conventional CD4+CD25- T cells (8,9). GITR is co-expressed with CD25 on the CD4+ T cells in human peripheral blood and patients with non-infectious uveitis and participate in the inflammatory process (10). The presence of tumor-specific Treg cells expressing CD25 and GITR at tumor sites may have a profound effect on the inhibition of T cell responses against cancer (11). Engagement of GITR on effector T cells by its ligand mediates resistance to suppression by CD4+CD25- T cells (12). GITRL is constitutively expressed on cultured retinal pigment epithelium and in high levels on photoreceptor inner segments (13). But little is known about the expression profiles of GITR in human peripheral T cells either in healthy individuals or in the patients with autoimmune diseases and cancer.

In the present study, we analyzed the expression of AITR and AITRL in PBMC and cancer cells of breast cancer patients compared with healthy individuals.
Materials and methods

Patients. A total of 20 females with breast cancer of stages I or II with a median age of 42 (range, 31-61) years were included in the investigation. All patients, tumor stage, histologic grading, axillary lymph node involvement and hormone receptor status were determined by routine histopathological examination. As controls, 20 healthy, age-matched females without clinical, radiological and serological evidence of the presence of breast cancer with a median age of 35 (range, 22-53) were included. Clinical characteristics of all patients are presented in Table I.

Clinical samples. The samples of breast cancer patients were from those who underwent an endoscopic biopsy, diagnostic or curative operations. Peripheral blood samples from breast cancer patients and healthy individuals were collected during the same period of this study. Tumor and normal tissues of breast cancer patients for flow cytometry and immunohistochemistry were from fresh specimens of resection surgery. All samples were obtained with the patients consent and were approved by our local Ethics Committee.

Cell isolation and culture. Peripheral blood mononuclear cells (PBMC) were isolated from breast cancer patients and healthy individuals by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) gradient centrifugation from freshly drawn heparinized peripheral venous blood, washed 3 times in 1x PBS and resuspended to 1x10^6 PBMC/ml in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and antibiotics at 37℃ in 5% CO2 incubator. To obtain monocytes, non-adherent cells of PBMC were removed following 2 h incubation at 37℃ in CO2 incubator and adherent cells were harvested. Monocytes were identified 96.9% CD14+ cells by flow cytometry. To acquire matured dendritic cells, monocytes were cultured with 100 U/ml of GM-CSF and 1.000 U/ml of IL-4 for 6 days. Immature monocyte-derived dendritic cells were cultured with 500 U/ml TNF-α. The matured dendritic cells were made up of 98% CD11c+ cells. The biopsy cancer tissues were minced into 1- to 3-mm fragments. Single tumor cells were released by enzymatic digestions with 0.25% Trypsin and 0.1% EDTA in 0.05 M NaHCO3 buffer at 4℃. After washing with 1x PBS the samples were thawed before assay. Nunc Maxisorb ELISA plates were coated overnight with 1 μg/ml anti-AITR (clone CE2; ImmunoMics) or anti-AITRL (clone BB4) mAbs for 6 h at 4℃. The samples were washed twice with FACS buffer. The proportion of AITR+ and AITRL+ cells was analyzed by single-color flow cytometry. Matching isotype antibodies were used as a control. All mAbs were the same and the flow cytometry was calibrated before each assay using FACSComp software (Beckton Dickinson).

Flow cytometry. PBMC were stimulated with 1 μg/ml of anti-CD3 (OKT3) and PHA (5 μg/ml) for 24 h or not. Cells were washed 1x PBS containing 1% BSA and 0.1% sodium azide (FACS buffer) once and subjected to flow cytometry in FACS Calibur to determine expression profiles of AITR and AITRL on lymphocyte subsets. PBMC were stained with FITC-conjugated anti-AITR or anti-AITRL mAbs and its expression was analyzed by single-color flow cytometry on FACS Calibur and CELLQuest (Beckton Dickinson, Mountain View, CA). To determine the expression profiles of AITR and AITRL on cell subsets, PBMC were stained with FITC-conjugated anti-AITR or anti-AITRL mAbs on PE-conjugated antibodies to T cell marker, and CD8 and B cell marker, CD19 and CD11c (R&D Systems, Minneapolis, MN) were used for cell typing, FITC-conjugated mouse IgG1 antibodies (BD Pharmingen, San Diego, CA) were used as controls.

Serum sAITR. Serum levels of soluble AITR (sAITR) and soluble AITRL (sAITRL) were measured by an enzyme-linked immunoabsorbent assay (ELISA). Serum samples were isolated from peripheral blood of all subjects by centrifugation and frozen immediately following collection. All assays were thawed before assay. Nunc Maxisorb ELISA plates were coated overnight with 1 μg/ml anti-AITR (clone CE2; ImmunoMics) or anti-AITRL (clone BB4, ImmunoMics) in 0.05 M NaHCO3 buffer at 4℃. After washing with 1x PBS containing 0.1% Tween-20, the plates were blocked with 4% BSA in 1x PBS for 1 h at 37℃. The serum samples were diluted with PBS containing 0.1% Tween-20 and 1% BSA and incubated for 2 h at 37℃. The plates were washed incubated with incubated biotinylated anti-AITR (clone 913) or anti-AITRL (clone BB4) for 1 h at 37℃. They were then washed and developed with TMB peroxidase substrate system (Endogen, BD Biosciences, MN, USA). The reaction was stopped after 20 min at room temperature (RT) with 0.1N

Table I. Characteristics of patients with breast cancer and of healthy control women.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Healthy controls</th>
<th>Patients with breast cancer stages I or II</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>Median age (range)</td>
<td>35 (22-53)</td>
<td>42 (31-61)</td>
</tr>
<tr>
<td>Metastasis</td>
<td>-</td>
<td>M0</td>
</tr>
</tbody>
</table>
H$_2$SO$_4$ and OD$_{450}$ nm was subsequently measured. Purified human recombinant AITR-GST or AITRL-GST (Immunomics) were used as standards. ELISA sensitivity was 50 pg/ml.

RT-PCR. mRNA expression of AITR and AITRL were determined by reverse transcriptase RT-PCR as previously described by Kwon et al (2). Total RNA was extracted from freshly isolated PBMC and tumor tissues using the RNeasy kit (Qiagen, Countaboeuf, France) following the manufacturer’s recommendations. The single-strand cDNA was synthesized using 1 μg of total RNA by reverse-transcription using an oligo-dT primer (GenoTec, Korea). Primer sequences were as follows: (a) AITR: 5'-GAG GAG TGC TGT TCC GAG T-3'; 5'-ACA CCC ACA GGT CTC CCA G-3'; and (b) AITRL: 5'-AAG CTG TGG CTC TTT TGC TC-3'; 5'-GAA TTG GGG ATT TGC CAG TA-3'. The samples were denatured at 95˚C for 30 sec, followed by 40 cycles of amplification (95˚C for 0 sec; 55˚C for AITR and 50˚C for AITRL, 60 sec; and 72˚C, 60 sec). The PCR products of AITR and AITRL were each 514 and 540 bp fragments. The amplified fragments were size-separated on a 1% agarose gel and visualized by ethidium bromide.

Confocal laser scanning microscopy. Tumor tissues were separately snap-frozen in Tissue-Tek OCT (Miles Diagnostics, Elkhart, IN, USA) and stored at -80˚C until used. Cryostat sections 6 μm thick were mounted on glass slides (Superior, Marienfeld, Germany). The glass slides were boxed and stored at -20˚C until immunological analysis. The slides were rinsed 3 times with 1x PBS for 10 min and blocked with 10% normal goat serum in 1x PBS for 1 h at room temperature. The slides were stained with FITC-conjugated anti-AITR (clone 621) and anti-AITRL (clone CE2) in the dark at room temperature for 1 h. After washing, slides were sealed with aqueous mounting media and analyzed by confocal laser scanning microscopy (LSM 510, Carl Zeiss, Heidelberg, Germany) equipped with Ar and HeNe lasers. Control mAb were used FITC-conjugated anti-mIgG at the same concentrations in each assay.

Statistical analysis. Statistical analysis was performed with software of SNPP for analyzing of AITRL data, which were shown as mean ± SD. The independent-samples t-test, Chi-square test and Person correlation analysis were assessed to compare variables of serum levels of sAITRL between BC patients and healthy individuals. A p-value of <5% was considered statistically significant.

Results

Expression of AITR and AITRL. At first we gated lymphocyte population from PBMC on forward- and side-scatter plot and then detected FITC-conjugated AITR$^+$ or AITRL$^+$ cells (Fig. 1). Expression level of AITR (Fig. 1a) showed higher levels (P<0.05) on PBMC of breast cancer patients (mean ± SD; 25.0±12.4%) than that of healthy individuals (15.1±9.58%) after stimulation. AITR was expressed on activated CD4$^+$/CD8$^+$ T cells and CD19$^+$ B cells in the lymphocyte population of healthy individuals (4.02±2.87%), but on the other hand it was constitutively expressed on resting cells of breast cancer patients (22.66±16.12%). AITRL (Fig. 1b) expressed low levels on resting PBMC of healthy individuals or did not (2.16%±0.86%), and its levels were increased after stimulation (22.07±9.89%). AITRL was constitutively expressed on resting PBMC (36.28±19.99%) of BC patients and slightly increased on activated PBMC (48.56±25.62%). AITRL expression was observed on CD4$^+$/CD8$^+$ T cells, CD19$^+$ B cells, monocytes and dendritic cells in breast cancer patients and its patterns were similar to AITR. AITR and AITRL were also highly expressed on monocytes and monocyte-derived dendritic cells in breast cancer patients and its patterns were similar to AITR. AITR and AITRL were also highly expressed on monocytes and monocyte-derived dendritic cells of breast cancer patients (Fig. 2). Both AITR (20.14±6.96) and AITRL (64.06±14.57) were highly expressed in cancer cells isolated from breast tissues of breast cancer patients (Fig. 3) compared with normal cells isolated from normal tissues (AITR, 20.14±6.96% and AITRL, 23.09±10.51%).

Serum sAITR and sAITRL. Serum sAITR and sAITRL levels were determined by ELISA with 20 breast cancer patients compared with healthy individuals (Fig. 4). Serum s-1BB in both the breast cancer patient group (mean ± SD; 170.8±108.9 pg/ml) and the healthy control group (54.9±60.7 pg/ml) detected low concentrations of sAITR. The serum levels of sAITR were remarkably elevated in breast cancer patients (1,429.3±1,043.5 pg/ml) compared with the healthy control group (170.8±108.9 pg/ml). The data suggest that the serum...
level of sAITRL is greatly increased in breast cancer patients and correlates with high expression of AITRL on PBMC of breast cancer patients.

**RT-PCR.** To identify the mRNA expression of AITR and AITRL on breast cancer cells of BC patients, we carried out RT-PCR (Fig. 5). RT-PCR analysis revealed an almost complete absence of AITRL mRNA in cancer cells isolated from breast tissues of BC patients. The integrity of the RNA preparation was confirmed by the detection of mRNA for the housekeeping β-actin (data not shown).

**Immunohistochemical analysis.** To confirm that breast cancer cells can express AITR and AITRL, we analyzed breast tissues of breast cancer patients by immunohistochemistry using anti-AITR and anti-AITRL mAbs compared with non-tumor normal tissues. The cancer tissues of breast cancer patients exhibited typical pathologic figures of breast cancer, including increased vascularity as shown by H&E staining (Fig. 6a). AITRL expression was observed in cancer tissues of breast cancer patients with rich regions of the tumors (Fig. 6b). AITRL expression was observed in tumor cells isolated from cancer tissues of breast cancer patients (Fig. 6c). In contrast, AITR expression was not detected in breast cancer cells of the breast tissue (data not shown).

**Discussion**

Expression of costimulatory molecules conferred the ability to deliver a costimulatory signal and improved the antigen presentation capability of the tumor cells to patient T cells in vitro (14). It has been demonstrated that breast cancer cells can escape immune surveillance through abnormal expression of MHC II antigen and CD80/CD86 (15, 16). A defective expression of CD54 and its regulation via TNF-α, CD80 and
Lymphocytes and blood vessels. GITR is a CD4+ T cell activation marker important for interactions between activated T cells and effector T cells of the immune system in breast cancer. KLH2 (2) concluded that AITR and AITRL are expressed in human umbilical vein endothelial cells (HUVEC) and primary endothelial cells in blood vessels and expressed in activated PBMC with healthy individuals, while they were constitutively expressed in PBMC with breast cancer patients. The expression of AITR and AITRL was observed in CD4+/CD8+ T cells and CD19+ B cells (data not shown). AITR and AITRL were highly expressed on monocytes and monocyte-derived dendritic cells of two groups with similar patterns (Fig. 2). We found that breast cancer cells can highly express AITR (Fig. 3). We confirmed that AITR was strongly expressed in breast cancer tissues by RT-PCR (Fig. 5) and confocal laser scanning microscopy (Fig. 6). AITR is expressed in PBMC of healthy individuals after TCR activation with PMA/ionomycin or anti-CD3 plus anti-CD28 mAbs (2). In contrast, AITR and AITRL are strongly expressed in PBMC with healthy individuals, while they were constitutively expressed in PBMC with breast cancer patients. The expression of AITR and AITRL was observed in CD4+/CD8+ T cells and CD19+ B cells (data not shown). AITR and AITRL were highly expressed on monocytes and monocyte-derived dendritic cells of two groups with similar patterns (Fig. 2). We found that breast cancer cells can highly express AITR (Fig. 3). We confirmed that AITR was strongly expressed in breast cancer tissues by RT-PCR (Fig. 5) and confocal laser scanning microscopy (Fig. 6). AITR is expressed in PBMC of healthy individuals after TCR activation with PMA/ionomycin or anti-CD3 plus anti-CD28 mAbs (2). In contrast, AITR and AITRL are constitutively expressed in human umbilical vein endothelial cells (HUVEC) and primary endothelial cells in blood vessels and its expression was up-regulated after stimulation with LPS. Therefore, KLH2 et al (2) concluded that AITR and AITRL is important for interactions between activated T lymphocytes and blood vessels. GITR is a CD4+ T cell activation marker similar to other T cell markers such as CD69, CD25 and HLA-DR human peripheral blood and its expression correlates with the clinical course of non-infectious uveitis (20). In GITR deficient mice, it was suggested that GITR might be important for the negative regulation of T cell activation (7). GITR, which is preferentially expressed on the surface of Treg, potentially provides a signal that abrogates Treg suppression (9). GITR is constitutively expressed on retinal pigment epithelium and photoreceptor inner segments in high levels and participates in the regulation of ocular inflammation (13). GITR may be the crucial factor for tumorigenesis and the aggressive biological behavior of human peripheral primitive neuroectodermal tumor (21). Our findings suggest that increasing expression of GITR and GITRL plays a role in T cell apoptosis and may have implications in understanding immunogenicity of breast cancer.

Serious cases of TNF superfamily, such as CD27, CD30, CD137, FasL and TNF-α, TRAIL have greatly generated stable soluble forms and selectively induced apoptosis in many transformed cells (22). A soluble Fas generated by several alternative mRNA splicing can bind FasL and block Fas-mediated apoptosis (23). Apoptosis is an important control mechanism in the regulation of tumor progression and metastasis because tumor growth depends on uncontrolled proliferation and the suppression of apoptosis (24). Gastro-intestinal tumors may escape FasL-dependent immune-cytotoxic attack by overexpressing DcR3 that blocks FasL (25). Serum sFas levels may be a valuable clinical prognostic factor in predicting an outcome of disease progression for patients with metastatic breast cancer (26). Soluble FasL was eluted from the surface of uveal melanomas specifically inhibited cytotoxic T lymphocyte lysis of tumor cells pretreated with an inhibitor of metalloproteases (27). sGITR triggered an inflammatory process in peritoneal membrane and neighboring fat tissues as an antagonist and blocks a tonic anti-inflammatory effect of GITRL (28). sGITR in mice induces GITR-dependent NF-κB activation and blocks in vitro suppression mediated by both resting and activated Treg cells (29). We found that serum sAITRL level was significantly increased in breast cancer patients compared with the healthy control and corresponds with surface expression levels of AITRL (Fig. 4). This result suggests that sAITRL may play a role in tumor cell survival of breast cancer.

NF-xB stimulates proliferation and blocks apoptosis in different cell types, including human breast cancers (4,5). Therefore, certain breast cancer cells rely on NF-xB for aberrant cell proliferation and simultaneously avoid apoptosis (5). NF-xB inhibits cell death and promotes faster cancer growth, migration and metastasis (30). AITR is able to trigger AITR-specific T cell activation with strong induction of NF-xB and TRAF-2 (2). We have further completed characterization of the mechanisms that regulate the magnitude and duration of AITRL expression which...
should offer potential therapeutic targets for modulation of tumor immune response.

In conclusion, we reported for the first time on an analysis of the expression of AITR and AITRL in peripheral blood and cancer cells of patients with breast cancer. Our study supports the hypothesis that AITR and AITRL may contribute to tumor growth and survival.

Acknowledgements

This study was supported by the Science Research Center Fund to the IRC at the University of Ulsan, by KOSEF (KRF2001-015-DP0553) and by grants from the Korean Research Foundation (DP0553).

References
